Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1997-10-22
|
pubmed:abstractText |
We studied the effects of 5 alpha-reductase inhibitor (finasteride) in the treatment of benign prostatic hyperplasia (BPH). This study is a randomized controlled trial. Sixty-two patients were treated with 5 alpha-reductase (finasteride 5 mg/day) and 61 patients (control group) with placebo for one year. Prostatic volume, maximal urine flow rate, AUA symptom scoring, residual urine volume and prostate-specific antigen (PSA) levels were evaluated at 3, 6, 9 and 12 months. In the first 6 months prostatic volume decreased rapidly (20.5%), in the second 6 months it decreased slowly and reached the maximal rate (23.3%). Maximal urine flow rate increased in the second 6 months. AUA symptom scores decreased first at 3 months and were 4.6 points lower at the end of the 12th month. There were no significant changes in residual volume. The 5 alpha-reductase inhibitor caused a 50% decrease in PSA levels, like in other studies. Because of the prolonged use of the drug, treatment with 5 alpha-reductase inhibitor is not tolerated by many patients and being expensive its future in the pharmacotherapy of BPH is unclear.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0301-1623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
323-30
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9285305-Aged,
pubmed-meshheading:9285305-Aged, 80 and over,
pubmed-meshheading:9285305-Cholestenone 5 alpha-Reductase,
pubmed-meshheading:9285305-Enzyme Inhibitors,
pubmed-meshheading:9285305-Finasteride,
pubmed-meshheading:9285305-Humans,
pubmed-meshheading:9285305-Male,
pubmed-meshheading:9285305-Middle Aged,
pubmed-meshheading:9285305-Oxidoreductases,
pubmed-meshheading:9285305-Prostatic Hyperplasia,
pubmed-meshheading:9285305-Treatment Outcome
|
pubmed:year |
1997
|
pubmed:articleTitle |
Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase.
|
pubmed:affiliation |
Department of Urology, Atatürk University School of Medicine, Research Hospital, Erzurum, Turkey.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|